tislelizumab
beigene
['lung', 'tislelizumab', 'gastric', 'rcc,(-irccs),(-srcc),(-urcc)', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)']
tislelizumab (anti-pd-1) + sbrt (all lesions) for oligomets ( 5 lesions) ccrcc in 15 pt cohort 9 imdc int, 6 imdc poor orr (pt-level): 33% (no cr) orr (lesion-level): 28% 1 g3 ae (heme) os&amp;pfs pending
sbrt evaluation w/ ici combos needed instead?
#gu23 
MD, MSc | @UofTUrology @SUO_YUO Fellow & @IHPMEUofT CEHCR PhD| Previously: @AUB_Lebanon and @MCG_Urology